Nootropics Index - Save on smarter supplements
Nootropics>Synthetic nootropics & research compounds>Unifiram
Synthetic nootropics & research compounds

Unifiram

Unifiram (DM-232) synthetic nootropic research compound

Unifiram (DM-232) is an experimental synthetic compound studied in animal memory models. Human cognitive benefit and safety are unestablished. It is distinct from Sunifiram (DM-235): compare exact chemical identity before comparing prices, and do not infer a human regimen from animal potency or vendor serving sizes.

CholinergicGlutamatergicSyntheticMostly Animal EvidenceInsufficient EvidenceLong Term Safety Unknown
Updated October 2026/5 min read/8 citations
Reviewed by the NootropicsIndex editorial team.Method: prioritize cited human research and official safety or regulatory sources; compare retailer-listed prices without endorsing products.Affiliate disclosure
01

What is it?

What Unifiram is

2

Unifiram is DM-232, a synthetic compound developed in an academic cognition-research program. Its experimental evidence concerns rodents and laboratory preparations. Online nootropic terminology does not make it an established human supplement.

Evidence snapshot1
Rodent memory-task results can suggest a research direction. They cannot establish whether healthy people gain useful memory, focus or productivity benefits, nor how strong those effects would be.

No evidence-based human dose

5

No evidence-based human oral dosage range was identified. Neither animal doses nor product-label amounts establish a safe or effective amount for people.

02

Names, aliases and forms

Research CodesDM-232; DM232
Cas Number272786-64-8
Pubchem Cid9861054
03

Mechanisms of action

AMPA-related mechanism hypothesis

2

Animal and tissue studies implicate AMPA-related glutamate signaling and acetylcholine release. AMPA receptors participate in fast excitatory communication between neurons; this mechanism evidence does not establish a clinical benefit or a human safety profile.

04

Potential effects and evidence map

Published research describes animal memory tasks and laboratory signaling studies, not demonstrated cognitive benefits in people. Human efficacy, pharmacokinetics and a clinical safety profile were not established in the literature located for this review.

Effect domainMagnitudeGrade
Memory / learning1
UnknownConfidence: Low

Unifiram affected memory tasks in animal experiments; a human memory or learning benefit has not been established.

Note Zero denotes no demonstrated human effect magnitude, not evidence that the compound has no biological activity.

0/5
D
05

Timing & effect horizon

Effect horizonUnknown
Unknown
Duration and cycle claims5

The sources located do not establish human onset, The time for blood levels to fall by half during the final elimination phase.Source, effect duration, tolerance or a cycling schedule. Animal testing intervals cannot fill those gaps.

06

Safety, side effects and risk profile

Why human risk is unknown5
Human safety evidence is insufficient to calibrate an ordinary healthy-adult oral-use risk score: a studied human dose, duration and adverse-event profile are not established. Unknown does not mean low risk. The available research does not establish the likelihood, severity or reversibility of harms, including long-term effects. Pregnancy and breastfeeding safety are also unestablished.
07

Interactions and cautions

Interactions are uncharacterized5

The cited literature does not establish human interactions with medicines, alcohol or other nootropics. AMPA-related and cholinergic findings do not predict which combinations are safe; Sunifiram anecdotes cannot establish Unifiram interaction risks.

08

Legal and regulatory status

U.S. identity registration is not approval8

As of 18 October 2026, the U.S. FDA substance database lists Unifiram as UNII N4024LN29G and explicitly explains that a UNII does not imply regulatory review or approval. This identity entry does not establish authorization as a dietary supplement or medicine. Sale and import requirements in other countries need separate local verification.

09

Practical buying and quality notes

  • For two listings of the same compound and stated purity, compare listed price divided by the total grams of that compound. A capsule count alone is not a comparable mass unit. This arithmetic compares asking prices; it does not establish a usable dose or verify product contents.6
  • Sunifiram is DM-235; Unifiram is DM-232 (CAS 272786-64-8). They are different compounds. Verify that the name, identifier and analytical report refer to the same substance before comparing listings.3
  • A certificate of analysis (COA) should identify the tested compound and batch and show what the laboratory actually measured. A purity percentage alone does not establish the identity of an online product, absence of every contaminant or human safety. The original research group specifically distinguished online purity documentation from missing clinical and toxicology evidence.5
10

FAQ

Is Unifiram proven to work in humans?

1

No established human benefit was identified in the sources reviewed. Positive results in animal memory experiments are a different level of evidence from a clinical trial.

What Unifiram dosage has been studied?

5

The cited experiments concern animals, not a validated regimen for human use. Vendor servings and forum protocols do not close that evidence gap.

How long does Unifiram last?

5

A reliable human duration or cycle length has not been established. Precise retailer or forum timing claims need human pharmacokinetic or clinical evidence before they can be relied on.

Is Sunifiram the same as Unifiram?

3

No. DM-235 and DM-232 have different chemical structures. Results and usage claims for one cannot automatically be transferred to the other.

What should I check before buying Unifiram?

5

Start with the exact compound and batch identity, then check whether an analytical report matches that batch and what its test methods cover. A price comparison or purity document cannot demonstrate human benefit or safety.

11

References

  1. Galeotti N, Ghelardini C, et al. AMPA-receptor activation is involved in the antiamnesic effect of DM 232 (unifiram) and DM 235 (sunifiram). Naunyn Schmiedebergs Arch Pharmacol. 2003.
  2. Romanelli MN, Galeotti N, Ghelardini C, et al. Pharmacological characterization of DM232 (unifiram) and DM235 (sunifiram), new potent cognition enhancers. CNS Drug Reviews. 2006;12(1):39-52.
  3. Manetti D, et al. Structure-activity relationship studies on unifiram (DM232) and sunifiram (DM235), two novel and potent cognition enhancing drugs. Bioorganic & Medicinal Chemistry. 2004.
  4. Martini E, et al. Enantioselective synthesis and preliminary pharmacological evaluation of the enantiomers of unifiram (DM232), a potent cognition-enhancing agent. Med Chem. 2005;1(5):473-480.
  5. Gualtieri F. Unifi nootropics from the lab to the web: a story of academic (and industrial) shortcomings. J Enzyme Inhib Med Chem. 2016;31(2):187-194. Published online 2015.
  6. PubChem. Unifiram, CID 9861054.
  7. NCBI Bookshelf. Glutamate Receptors. Neuroscience, 2nd edition.
  8. U.S. FDA Substance Registration System. Unifiram, UNII N4024LN29G. Accessed 18 October 2026.
Note

This page is informational and summarizes available evidence. It is not medical advice, a recommendation, or a substitute for guidance from a qualified clinician.